New triple inhaler shows promise for advanced COPD lungs
NCT ID NCT04876677
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether switching to a stronger, extrafine triple inhaler (CHF5993) could improve lung function in 25 people with advanced COPD. Participants were current or former smokers aged 40 or older. The study used special lung imaging to measure changes in airway volume and airflow resistance.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC OBSTRUCTIVE PULMONARY DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
AZ Delta
Roeselare, Belgium
-
AZ Zeno Knokke-Heist
Knokke, Belgium
-
CRU Hungary Ltd
Miskolc, Hungary
-
Dr. Kenessey Albert Hospital
Balassagyarmat, Hungary
-
Medlmprove BV
Kontich, 2550, Belgium
-
National Koranyi Institute for TB and Pulmonology
Budapest, Hungary
-
OLV Hospital Aalst
Aalst, Belgium
-
Pneumocare Scrl
Erpent, Belgium
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Smart breathing machines at home: a new way to predict COPD crises?
- Breathing easy? new X-Ray method may spot COPD decline early
- Could a common heart drug cut COPD hospitalizations?
- Which inhaler breathes better? a Head-to-Head COPD showdown
- Could tiny lung valves revive heart and muscle strength in COPD?
- One lung or two? surgery trial aims to find the best approach for severe COPD